The planned facility is envisioned to produce hundreds of fusion machines annually; TRIDEC will coordinate site evaluation, ...
The trial also reported complete symptom resolution at 11.95 hours, no safety signals, and regulatory applications under ...
CMS rated Clover’s HMO plan 4.5 stars; with 20 measures included, its PPO rating would be 4.5. Clover’s HEDIS score was 4.82 ...
Secured capacity totals about 273.5MW, or about 78% of a target of up to 350MW by Q1 2028; full campus delivery is targeted ...
In ATOMIC, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy versus 76% with chemotherapy alone; Roche is pursuing European filings.
In the 712-patient ATOMIC trial, 36-month disease-free survival was 86% with Tecentriq plus chemotherapy, versus 76% with chemotherapy alone.
Underwriters may buy up to 300,000 more shares under a 30-day option. Closing is expected Oct. 19; proceeds are intended for a life-sciences loan commitment.
Crescent plans to use proceeds for part of the cash consideration for Devon’s Eagle Ford assets acquisition, expected to close in Q4 2026 or early 2027.
Shareholders approved the split Sept. 29. Ownership percentages stay the same except for fractional-share adjustments; book-entry holders need no action.
Recent: Retension Pharmaceuticals Announces Pricing of Initial Public Offering . Track all RTSN press releases, SEC filings, and market updates. Latest RTSN news updated today, October 8.
Net proceeds and existing cash are intended to complete Phase 2b and prepare for a planned Phase 3 trial of RTN-001; the IPO ...
The five-day program runs Oct. 7-11; remaining care packages will go to people in need, and NBA legends and coaches will ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results